Omalizumab for chronic urticaria in children younger than 12 years

Ann Allergy Asthma Immunol. 2019 Aug;123(2):208-210.e2. doi: 10.1016/j.anai.2019.05.003. Epub 2019 May 11.

Authors

Taha Al-Shaikhly¹, Jamie A Rosenthal¹, Andrew G Ayars¹, Daniel H Petroni²

Affiliations

¹ Department of Medicine, University of Washington, Seattle Washington.
² Department of Medicine, University of Washington, Seattle Washington; Northwest Asthma and Allergy Center, Seattle, Washington; Seattle Allergy & Asthma Research Institute, Seattle, Washington. Electronic address: dpetroni@seattleallergy.org.

PMID: 31082483
DOI: 10.1016/j.anai.2019.05.003

No abstract available

Publication types

Letter
Review

MeSH terms

Angioedema / pathology
Anti-Allergic Agents / therapeutic use*
Child
Child, Preschool
Chronic Urticaria / drug therapy*
Chronic Urticaria / pathology
Female
Humans
Male
Omalizumab / therapeutic use*
Treatment Outcome

Substances

Anti-Allergic Agents
Omalizumab